News and Research
Immune System
Chicken Pox Vaccine Effectiveness Decreases After First
Year, But Still Yields Excellent Protection From The Virus
2-18-2004
New Haven, Conn. -- Yale researchers have found a major
decrease in the effectiveness of varicella (chicken pox)
vaccine after the first year of vaccination, but the vaccine
is still very effective overall.
"The
effectiveness of the varicella vaccine does drop substantially
from 99 percent the first year after vaccination to 84 percent
two to eight years after vaccination," said first author
Marietta Vazquez, M.D., associate research scientist in
the Department of Pediatrics at Yale School of Medicine.
"But eight years after vaccination, the overall effectiveness
is 87 percent, which is still excellent."
The
study, published in the February 18 issue of Journal of
the American Medical Association, also suggests that the
vaccine might be less effective in the first year after
vaccination if it is administered to children less than
15 months of age. Vazquez said this difference in effectiveness
disappears after the first year and overall is not significant.
|
|
The ongoing study conducted over the past seven years
addresses concerns about varicella outbreaks in highly immunized groups
that have raised controversy about the effectiveness of the varicella
vaccine. The authors assessed whether the effectiveness of varicella
vaccine is affected either by time since vaccination or age at the
time of vaccination. They studied 339 children ages 13 months or older
who were clinically diagnosed with chicken pox after they had been
vaccinated with varicella. Two controls were selected for each study
participant, matched by age and pediatric practice.
The researchers found the significant decrease in
effectiveness one year after vaccination, but most cases of breakthrough
disease are mild.
"The vaccine's effectiveness against moderate
or severe disease is excellent throughout the period of the study,"
said Vazquez.
Vazquez and her team stress that it will be important
to continue monitoring effectiveness of the vaccine since boosts to
immunity from exposure to varicella will become increasingly rare
as the incidence of varicella diminishes.
Other authors on the study included senior investigator
Eugene D. Shapiro, M.D., Linda M. Niccolai and Catherine E. Muchlenbein
of Yale; and Philip S. LaRussa, M.D., Anne A. Gershon, M.D. and Sharon
P. Steinberg of Columbia University.
Citation: Journal of the American Medical Association,
February 18, 2004-Vol. 291, No. 7.
This article has been adapted from a news release
issued by Yale University, www.yale.edu.
Next - Back
to Immune System Support